专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020236973A1 COMPOSITIONS AND METHODS OF MANUFACTURING TRIVALENT FILOVIRUS VACCINES 审中-公开
公开(公告)号：WO2020236973A1
公开(公告)日：2020-11-26
申请号：PCT/US2020/033864
申请日：2020-05-20
申请人： SOLIGENIX, INC. , UNIVERSITY OF HAWAII
发明人： DONINI, Oreola , LEHRER, Axel
IPC分类号： A61K39/00 , A61K39/02 , A61K39/07 , A61K39/12 , A61K39/39
摘要： Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use. Also disclosed is a vaccine composition comprising at least two antigens, wherein each antigen is specific to a different genus of filovirus and which also comprises at least one nano-emulsion adjuvant.

2. 发明申请

WO2022020815A1 ANTIBODY/ADJUVANT COMPOSITIONS AND METHODS OF IMMUNE RESPONSE GENERATION AGAINST CORONAVIRUSES 审中-公开
公开(公告)号：WO2022020815A1
公开(公告)日：2022-01-27
申请号：PCT/US2021/043236
申请日：2021-07-26
申请人： SOLIGENIX, INC. , UNIVERSITY OF HAWAII
发明人： DONINI, Oreola , LEHRER, Axel
IPC分类号： A61K39/00 , A61K39/12 , A61K39/215 , A61K39/295 , A61P11/00 , A61P31/12
摘要： Recombinant vaccine compositions combined with a specified adjuvant to deliver a robust immune response against coronaviruses for inducing protective immunity to a coronavirus comprising providing a stable immunogenic composition capable of eliciting a robust and durable immune response to the coronavirus, wherein the composition comprises a protein subunit comprising a recombinant protein specific to the coronavirus and at least one adjuvant.

3. 发明公开

EP3972637A1 COMPOSITIONS AND METHODS OF MANUFACTURING TRIVALENT FILOVIRUS VACCINES 审中-实审
公开(公告)号：EP3972637A1
公开(公告)日：2022-03-30
申请号：EP20810813.4
申请日：2020-05-20
申请人： Soligenix, Inc. , University of Hawaii
发明人： DONINI, Oreola , LEHRER, Axel
IPC分类号： A61K39/00 , A61K39/02 , A61K39/07 , A61K39/12 , A61K39/39

4. 发明申请

WO2015038264A1 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 审中-公开
标题翻译：用于治疗口腔粘膜炎的新型肽和模拟物
公开(公告)号：WO2015038264A1
公开(公告)日：2015-03-19
申请号：PCT/US2014/050516
申请日：2014-08-11
申请人： SOLIGENIX, INC. , DONINI, Oreola , ROZEK, Annett , LEE, Jackson , NORTH, John , ABRAMS, Michael
发明人： DONINI, Oreola , ROZEK, Annett , LEE, Jackson , NORTH, John , ABRAMS, Michael
IPC分类号： C07K7/00
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and coiitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis "window" with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and / or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
摘要翻译：化学诱导的粘膜炎，放射诱导的粘膜炎，中性粒细胞减少性感染和脑炎的模型中获得的临床前数据表明口腔粘膜炎是先天性防御调节剂（IDR）肽的有希望的指标。 IDR在小鼠和仓鼠粘膜炎模型中获得的临床前效力结果表明，取决于化疗或放射线暴露的持续时间，每三天给药应能够以7至14次剂量覆盖粘膜炎“窗口”。 IDRs还显示了化疗引起的口腔和胃肠粘膜炎的小鼠模型的功效，与化疗和/或辐射损伤的先天免疫应答的反应一致。 IDRs在各种鼠感染模型中，在存在或不存在抗生素治疗的同时，也有效减少细菌负担并改善生存。

5. 发明申请

WO2023283444A1 DERMATOLOGICAL COMPOSITIONS AND METHODS OF TREATMENT AGAINST CUTANEOUS T-CELL LYMPOMA 审中-公开
公开(公告)号：WO2023283444A1
公开(公告)日：2023-01-12
申请号：PCT/US2022/036551
申请日：2022-07-08
申请人： SOLIGENIX, INC.
发明人： DONINI, Oreola , STRAUBE, Richard , SCHABER, Christopher
IPC分类号： A61K36/185 , A61K9/06 , A61K36/38 , A61P35/00 , A61Q19/00
摘要： A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm2 and increases to a maximum dose of about 12 J/cm2.

6. 发明申请

WO2023283444A8 DERMATOLOGICAL COMPOSITIONS AND METHODS OF TREATMENT AGAINST CUTANEOUS T-CELL LYMPOMA 审中-公开
公开(公告)号：WO2023283444A8
公开(公告)日：2023-01-12
申请号：PCT/US2022/036551
申请日：2022-07-08
申请人： SOLIGENIX, INC.
发明人： DONINI, Oreola , STRAUBE, Richard , SCHABER, Christopher
IPC分类号： A61K36/185 , A61K9/06 , A61K36/38 , A61P35/00 , A61Q19/00 , A61B2503/42 , A61B5/0068 , A61B5/0071 , A61B5/4331 , A61B5/441 , A61B5/7267 , G06V10/82
摘要： A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm2 and increases to a maximum dose of about 12 J/cm2.

7. 发明申请

WO2015061682A2 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF MACROPHAGE ACTIVATION SYNDROME 审中-公开
标题翻译：用于治疗巨噬细胞活化综合症的新型肽和类似物
公开(公告)号：WO2015061682A2
公开(公告)日：2015-04-30
申请号：PCT/US2014/062173
申请日：2014-10-24
申请人： SOLIGENIX, INC. , DONINI, Oreola , SCHABER, Christopher , HORGAN, Kevin
发明人： DONINI, Oreola , SCHABER, Christopher , HORGAN, Kevin
IPC分类号： A61K38/08 , C07K7/06 , A61K31/485
CPC分类号： A61K38/08 , A61K31/485 , C07K7/06 , A61K2300/00
摘要： Innate Defense Regulators (IDRs) interact with intracellular signaling events and modulate the innate defense response. Whereas much of the initial work with the IDRs focused on their role in fighting infection, recent results in animal models of chemotherapy- or radiation-induced mucositis and wound healing suggest that IDRs can be beneficial during the responses to a broader range of damage-inducing agents beyond pathogens. RIVPA (SEQ ID NO. 5), has demonstrated safety in humans and efficacy in animal models of fractionated radiation-induced and chemotherapy-induced oral mucositis, in models of chemotherapy induced damage to the gastro-intestinal tract and in models of local and systemic Gram-positive and Gram-negative infection in immunocompetent and immunocompromised hosts. Based on this information, we propose the use of RIVPA (SEQ ID NO. 5) and / or other IDRs (Table 1) as a novel treatment for Macrophage Activation Syndrome.
摘要翻译：先天防务监管机构（IDR）与细胞内信号事件相互作用并调节先天防御反应。尽管IDR的许多初步工作都集中在抗感染的作用上，但化疗或放射诱导的粘膜炎和伤口愈合的动物模型的最新结果表明，IDRs在更广泛的损伤诱导反应过程中可能是有益的超越病原体的药物。 RIVPA（SEQ ID NO.5）已经证明在人类中的安全性和在分次辐射诱导的和化学疗法诱导的口腔粘膜炎的动物模型，化疗诱导的胃肠道损伤模型和局部和全身模型中的功效革兰氏阳性和革兰氏阴性感染免疫活性和免疫功能低下的宿主。基于这些信息，我们提出使用RIVPA（SEQ ID NO.5）和/或其他IDR（表1）作为巨噬细胞激活综合征的新型治疗。

8. 发明公开

EP3044229A1 NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS 有权
标题翻译：新型肽及其类似物口服粘膜炎的治疗
公开(公告)号：EP3044229A1
公开(公告)日：2016-07-20
申请号：EP14844276.7
申请日：2014-08-11
申请人： Soligenix, Inc. , Donini, Oreola , Rozek, Annett , Lee, Jackson , North, John , Abrams, Michael J.
发明人： DONINI, Oreola , ROZEK, Annett , LEE, Jackson , NORTH, John , ABRAMS, Michael
IPC分类号： C07K7/00
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式